AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
-3.57%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$4.05B
AUM Growth
+$4.05B
(+6.2%)
Cap. Flow
+$420M
Cap. Flow
% of AUM
10.38%
Top 10 Holdings %
Top 10 Hldgs %
28.84%
Holding
165
New
48
Increased
47
Reduced
28
Closed
27
Top Buys
| 1 |
Incyte
INCY
|
$96.8M |
| 2 |
Five Below
FIVE
|
$67.4M |
| 3 |
Pacira BioSciences
PCRX
|
$52.4M |
| 4 |
Baxter International
BAX
|
$46.6M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$42.2M |
Top Sells
| 1 |
Campbell Soup
CPB
|
$59.8M |
| 2 |
lululemon athletica
LULU
|
$56.9M |
| 3 |
Alkermes
ALKS
|
$47.6M |
| 4 |
Target Hospitality
TH
|
$46.3M |
| 5 |
Amazon
AMZN
|
$44.3M |
Sector Composition
| 1 | Healthcare | 65.1% |
| 2 | Consumer Discretionary | 11.61% |
| 3 | Consumer Staples | 9.79% |
| 4 | Communication Services | 4.98% |
| 5 | Technology | 3.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Incyte
INCY
$16.5B
| $163M | 2.76% | 2,372,000 +1,408,000 | +146% | +$96.8M |
|
2
Bristol-Myers Squibb
BMY
$96B
| $139M | 2.36% | 2,356,000 +678,000 | +40% | +$40.1M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $126M | 2.13% | 710,000 +50,000 | +8% | +$8.85M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $115M | 1.95% | 636,000 +36,000 | +6% | +$6.53M |
|
5
Travere Therapeutics
TVTX
$1.56B
| $115M | 1.95% | 4,748,000 -1,000,000 | -17% | -$24.3M |
|
6
Biogen
BIIB
$19.4B
| $105M | 1.78% | 372,000 +4,000 | +1% | +$1.13M |
|
7
Enanta Pharmaceuticals
ENTA
$180M
| $104M | 1.77% | 1,836,000 -164,000 | -8% | -$9.32M |
|
8
Supernus Pharmaceuticals
SUPN
$2.53B
| $104M | 1.76% | 3,900,000 +576,000 | +17% | +$15.4M |
|
9
Avalo Therapeutics
AVTX
$122M
| $98.1M | 1.66% | 45,000,000 +5,900,000 | +15% | +$12.9M |
|
10
PTC Therapeutics
PTCT
$3.92B
| $96.6M | 1.64% | 2,596,000 +504,000 | +24% | +$18.8M |
|
11
Iovance Biotherapeutics
IOVA
$807M
| $90M | 1.52% | 3,648,000 +276,000 | +8% | +$6.81M |
|
12
Madrigal Pharmaceuticals
MDGL
$9.76B
| $82.7M | 1.4% | 1,036,000 +444,000 | +75% | +$35.4M |
|
13
Zymeworks
ZYME
$1.12B
| $73.3M | 1.24% | 2,524,000 +524,000 | +26% | +$15.2M |
|
|
14
Alkermes
ALKS
$4.78B
| $72.7M | 1.23% | 2,356,000 -1,544,000 | -40% | -$47.6M |
|
|
15
Five Below
FIVE
$8B
| $67.4M | 1.14% | +381,266 | New | +$67.4M |
|
16
Energizer
ENR
$1.88B
| $64.4M | 1.09% | 1,648,000 +376,000 | +30% | +$14.7M |
|
17
argenx
ARGX
$43.6B
| $62.8M | 1.06% | 208,000 +30,000 | +17% | +$9.06M |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $60.5M | 1.03% | 100,000 -56,000 | -36% | -$33.9M |
|
19
Burlington
BURL
$18.3B
| $60.4M | 1.02% | 212,994 -43,468 | -17% | -$12.3M |
|
20
Medtronic
MDT
$119B
| $56.4M | 0.96% | 450,000 -66,000 | -13% | -$8.27M |
|
21
Academy Sports + Outdoors
ASO
$3.56B
| $55.9M | 0.95% | 1,395,710 +470,384 | +51% | +$18.8M |
|
22
Catalyst Pharmaceutical
CPRX
$2.52B
| $53M | 0.9% | 10,000,000 | – | – |
|
23
Haemonetics
HAE
$2.63B
| $52.9M | 0.9% | 750,000 +126,000 | +20% | +$8.89M |
|
24
AB InBev
BUD
$122B
| $52.8M | 0.89% | 936,000 +480,000 | +105% | +$27.1M |
|
|
25
Pacira BioSciences
PCRX
$1.2B
| $52.4M | 0.89% | +936,000 | New | +$52.4M |
|